Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Inflation uncertainty returns as pricing pressures shift
After a period of stabilising inflation, UK personal lines insurers are once again facing a more uncertain outlook. The recent conflict in Iran may
Smart isn’t enough insurers must scale operations to succeed
Even the most advanced pricing strategies fail without execution at scale. Discover how insurers can operationalize insight through collaboration, clo
The Pensions Commissions report: what employers need to know
The Second Pensions Commission has published its interim report. At 190 pages, it is detailed and wide-ranging. But for many employers, much of it wil

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.